Login / Register The Most Trusted Name in Medical Education

Allergy & Immunology

From asthma to shingles, we offer complimentary CME courses for a variety of Allergy & Immunology CME credits.

910701 116 x 144

Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Format: Webcast Series

This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making. 

Take Course »

 

Credits: Up to 1.00 AMA PRA Category 1 Credit(s)™
Elsevier SITC ASCO 2018 01 Web 116x140 webcast

The IO Quiz Show: Biomarkers for Immunotherapy

Format: Webcast

This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credits™
910694 116 x 140

Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis and Treatment

Format: Webcast

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
Elsevier CNS 2017 10 Web 116x140 v1

THE IO QUIZ SHOW: BIOMARKERS FOR IMMUNOTHERAPY

Format: Live Symposium

Join us to test and expand your knowledge on the increasingly important role of biomarkers in immuno-oncology. Three leading experts will challenge you with quiz questions that lay the basis for in-depth discussions supported by slide presentations. In this interactive learning experience we will examine the tumor microenvironment and address the evidence base and the future potential of current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. You will also learn about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for your daily clinical practice.

Take Course »

Credits: 1.5 AMA PRA Category 1 Credit(s)™
2017 19 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research on AD presented at the American Academy of Dermatology 2017 Annual Meeting.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910687 116x140

Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary Care

Format: Webcast

This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.  

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™ or 1.00 Nursing Contact Hours
910728 116 x 140

An Update on Scientific Advances and Clinical Strategies in Chronic Obstructive Pulmonary Disease (COPD) from the ATS 2017 International Conference

Format: Conference Reporter

The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
116x140 RGNRN ATS ASTHMA2

CLINICAL ISSUES IN SEVERE ASTHMA: CONSENSUS AND CONTROVERSIES ON THE ROAD TO PRECISION MEDICINE

Format: Webcast

This CME-accredited Clinical IssuesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the management of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate a series of topics related to the evaluation and long-term treatment of various severe asthma phenotypes. Activity topics include classification of severe asthma, disease biomarkers, comorbidity management, and current and emerging targeted biologic therapies. The goal is to provide clinician learners with the latest evidence and a fresh perspective on evolving management paradigms for severe asthma.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910730 LC 116 x 140

Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning Center

Format: Resource Center

Welcome to Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning Center. The Learning Center provides you with free access to the latest clinical information relating to the diagnosis and management of COPD. The COPD Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles and resources for healthcare providers who treat patients with COPD.

Go to Learning Center »

910730 116 x 141

CONFRONTING THE CHALLENGE OF COPD: WHAT IS NEW IN THE APPROACHES TO DIAGNOSIS, TREATMENT, AND PATIENT OUTCOMES

Format: Webcast

Most aspects of chronic obstructive pulmonary disease (COPD) have been undergoing renewed scrutiny in recent years, with research investigating the entire spectrum of disease development and progression, the genetic phenotypes and risk factors, disease heterogeneity, refinements in diagnostic approaches, advances in treatment options, and so forth. This activity provides insights into new approaches to identifying patients with undiagnosed COPD, the importance of early initiation of pharmacologic treatment in a guideline-congruent manner, and the importance of repeated patient training in correct inhaler technique in order to improve adherence and patient outcomes.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910729 116 x 140

CHEST 2017: AN UPDATE ON SCIENTIFIC ADVANCES AND CLINICAL STRATEGIES IN COPD

Format: Conference Reporter

The CHEST Annual Meeting 2017 was held in Toronto, Ontario, Canada, October 28–November 1, 2017. As the premier chest medicine education meeting for clinicians, CHEST unites leaders to discuss current pulmonary, critical care, and sleep medicine topics. In this activity, 2 experts summarize the key learnings from this year’s Annual Meeting, focusing on chronic obstructive pulmonary disease (COPD).

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit™
116x140

Looking Beneath the Surface in Atopic Dermatitis: Targeting Immune Dysregulation and Delivering Comprehensive Care

Format: Webcast

This Interactive Exchange™ program will open with a brief 3D-animated video focused on the pathophysiologic underpinnings of atopic dermatitis. Expert faculty will then discuss best practices for comprehensive patient evaluations and the clinical profiles of systemic treatment options for patients with moderate-to-severe disease. With an overall goal of improving patient outcomes, this educational session has been designed to allow internationally recognized experts to translate the latest published evidence into actionable recommendations for individualized patient care.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
910647e 116 x 140

Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment

Format: Webcast

The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors. 

Register »

 

Credits: 1.25 AMA PRA Category 1 Credit(s)™
DERM 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.  

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™

See All Courses »